Ocrevus (Ocrelizumab)

Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a 150 mg per vial solution for injection for subcutaneous use. It treats relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adult patients.

GNH USA supplies Ocrevus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ocrevus is indicated as a disease‑modifying therapy for multiple sclerosis, targeting B‑cell activity.

- Relapsing‑Remitting Multiple Sclerosis: reduces frequency of clinical relapses and slows disability progression. - Primary Progressive Multiple Sclerosis: delays accumulation of disability in adults. - Active Disease Activity in Multiple Sclerosis: helps control MRI‑detected lesions and clinical activity.

Ocrevus may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions: flushing, rash, pruritus, or mild fever. - Upper respiratory tract infections: nasopharyngitis, sinusitis, or cough. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects: - Severe infections: opportunistic infections such as tuberculosis or viral hepatitis. - Hepatitis B reactivation: liver inflammation in previously infected individuals. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain infection. - Malignancies: increased incidence of certain cancers reported in clinical trials.

When prescribing Ocrevus, clinicians should consider several precautionary measures to ensure patient safety.

- Screening: test for active hepatitis B infection before initiating therapy. - Vaccination: administer required vaccines, especially live vaccines, prior to treatment. - Monitoring: regularly assess complete blood counts and liver function tests during therapy. - Infection risk: advise patients to report signs of infection promptly and avoid exposure to contagious diseases. - Pregnancy: avoid use during pregnancy; discuss contraception and potential risks with women of childbearing potential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Ocrevus can interact with other medicines, influencing its safety or efficacy.

Major Interactions (Avoid): - Live vaccines: concurrent administration may lead to severe infection due to immunosuppression. - Antiviral therapy for hepatitis B: may be insufficient without prophylactic antiviral coverage.

Moderate Interactions (Monitor Closely): - Immunosuppressive agents: combined use may increase infection risk. - CYP450 substrates: no direct metabolism, but monitor for additive immunosuppression. - Concomitant monoclonal antibodies: overlapping mechanisms may heighten adverse event profile.